Last night’s excitement was tempered after I attended this morning’s huge presentation by a number of international myeloma docs. Over 2000 ASH members also attended. Some pertinent info. But most of the data was annoyingly frustrating! Why are we still measuring myeloma drug efficacy against melphalan and prednisone and thalidomide? I don’t care if the patient isn’t a transplant candidate. Stop it! Compare and contrast the new drugs against Velcade and Revlimid. Why are we even using melphalan anymore, anyway? What about the link to leukemia when it is used over an extended period of time? Stop it! Now, I understand that melphalan and Cytoxan are making a come-back. As a last resort, some oncologists are going back to melphalan and finding it effective in patients who are no longer responding to Revlimid or Velcade. I also see Cytoxan is being used in combination with a number of the novel therapies in promising combination studies–some being presented here this week. But please, please stop using melphalan as a standard of care. Hear that researchers–Hematologists– Oncologists–The FDA. WE ARE WASTING TIME!
I describe my visit later in the morning to the “poster hall” on my other blog, www.HelpWithCancer.Org. Check it out! I will get back to you later this afternoon with some (hopefully) more uplifting and exciting news about several of the new therapies. But remember, most of the myeloma data is being presented Monday and Tuesday.
Feel good and keep smiling! Pat